Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Paclitaxel 7pembrolizumab 6olaparib 5Carboplatin 4Bevacizumab 4tisotumab vedotin 2niraparib 2mirvetuximab soravtansine 2durvalumab 2defactinib 2Topotecan 2Taxes 2Saline Solution 2Immunoglobulin G 2Disulfides 2Cisplatin 2ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1sodium thiosulfate 1sapanisertib 1sacituzumab govitecan 1rucaparib 1relatlimab 1relacorilant 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1liposomal doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × liposomal doxorubicin × Gynecologic × Clear all
NCT04209855 2025-08-27

MIRASOL

AbbVie

Phase 3 Completed
453 enrolled 18 charts 1 FDA
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡